In a climate where so much time and energy is spent trying to tackle human disease, Monday’s Nobel Prize in Medicine is a welcome reminder of the value of pursuing research that scratches a scientific itch. Sometimes, that work might lead to a new understanding of human biology.
“Curiosity research is very important,” said Olle Kampe, member of the Nobel Committee for Physiology or Medicine, in announcing the prize to Victor Ambros, a professor at the University of Massachusetts Medical School, and Gary Ruvkun, at Harvard Medical School, for discovering so-called “microRNA.”
MicroRNA is one of a handful of biological systems that carefully orchestrate when, where and how intensely DNA should operate.
“They were looking at two worms that looked a bit funny and decided to understand why. And then they discovered an entirely new mechanism for gene regulation. I think that’s beautiful,” Kampe said.
The fundamental discoveries underpinning the award were conducted in a lowly roundworm. C elegans is a millimeter-long organism made up of a manageable 1,000 cells (Humans have somewhere between 28 and 36 trillion) yet also boasts a surprising sophistication that has made it a workhorse in research labs. In fact, this is the third set of scientists that can thank the organism for their Nobel nod.
Studying the roundworm allowed Ambros and Ruvkun to add needed nuance to biology’s central dogma that DNA is copied to RNA, which then is translated into proteins inside cells. However, that simple, linear story cannot address a fundamental question: If each of our trillions of cells carries the exact same genetic blueprint, how can a neuron look and behave so differently from, say, heart tissue or a muscle cell? As the researchers helped explain, it is all about when various proteins are turned on and off — a process that these small stretches of RNA play a vital role in regulating.
Understanding this deeper layer of gene regulation took decades. After Ambros described the first microRNA in 1993, it was seven more years before Ruvkun unveiled the second one. Soon it became clear that humans, too, shared these molecules, and the field exploded as researchers identified the snippets of code in various organisms.
While microRNA’s central role in regulating gene expression has not yet directly led to approved treatments or a groundbreaking vaccine, that does not mean that microRNA will not one day have an impact on our health. The discovery has already been vital to our knowledge of human disease.
MicroRNAs can tamp down expression of genes that allow healthy cells to go through their normal process of dying and cause the kind of uncontrolled cell growth that is a hallmark of cancer, said Matthew Disney, a chemistry professor at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology.
There is already compelling evidence that microRNAs are misbehaving in cancers such as so-called “triple-negative” breast cancer and brain cancer.
While turning microRNA into a diagnostic or targeting it with a medicine is tricky, academic scientists and biotech companies are hard at work on it. Disney is the founder of one of several biotech companies devoted to tapping into the therapeutic potential of harnessing microRNA. Given that microRNA levels are out of whack in so many diseases, others are working on ways to use the tiny molecules as a diagnostic tool.
The discovery of microRNA also emphasizes the importance of all the dark matter in our genome. Of the several billion base pairs that make up a human genome, only a small portion comprise the recipes for proteins. So what is the rest of that so-called “non-coding” material for? Over the past few decades, scientists have started to understand that it is far from junk — rather, buried within is the code for vital molecules, like microRNA.
We cannot lose sight of the value of these kinds of astonishing, foundational discoveries.
“Our government has gone more and more towards funding the type of research that is only connected to a disease,” said chemist Thomas Cech, who won the Nobel Prize in Chemistry in 1989 for a discovery that helped illuminate RNA’s essential role in life.
However, these foundational breakthroughs in biology are what lay the groundwork for better understanding human health.
This prize underscores the need to strike the right balance between basic research and direct applications to medicine. As Ambrose’s and Ruvkun’s work makes clear, no matter how much we think we know about our inner workings, biology has a way of reminding us how much left there is to discover.
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, healthcare and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Concerns that the US might abandon Taiwan are often overstated. While US President Donald Trump’s handling of Ukraine raised unease in Taiwan, it is crucial to recognize that Taiwan is not Ukraine. Under Trump, the US views Ukraine largely as a European problem, whereas the Indo-Pacific region remains its primary geopolitical focus. Taipei holds immense strategic value for Washington and is unlikely to be treated as a bargaining chip in US-China relations. Trump’s vision of “making America great again” would be directly undermined by any move to abandon Taiwan. Despite the rhetoric of “America First,” the Trump administration understands the necessity of
US President Donald Trump’s challenge to domestic American economic-political priorities, and abroad to the global balance of power, are not a threat to the security of Taiwan. Trump’s success can go far to contain the real threat — the Chinese Communist Party’s (CCP) surge to hegemony — while offering expanded defensive opportunities for Taiwan. In a stunning affirmation of the CCP policy of “forceful reunification,” an obscene euphemism for the invasion of Taiwan and the destruction of its democracy, on March 13, 2024, the People’s Liberation Army’s (PLA) used Chinese social media platforms to show the first-time linkage of three new
If you had a vision of the future where China did not dominate the global car industry, you can kiss those dreams goodbye. That is because US President Donald Trump’s promised 25 percent tariff on auto imports takes an ax to the only bits of the emerging electric vehicle (EV) supply chain that are not already dominated by Beijing. The biggest losers when the levies take effect this week would be Japan and South Korea. They account for one-third of the cars imported into the US, and as much as two-thirds of those imported from outside North America. (Mexico and Canada, while
I have heard people equate the government’s stance on resisting forced unification with China or the conditional reinstatement of the military court system with the rise of the Nazis before World War II. The comparison is absurd. There is no meaningful parallel between the government and Nazi Germany, nor does such a mindset exist within the general public in Taiwan. It is important to remember that the German public bore some responsibility for the horrors of the Holocaust. Post-World War II Germany’s transitional justice efforts were rooted in a national reckoning and introspection. Many Jews were sent to concentration camps not
RSS